Australian-based regenerative medicine company Mesoblast has expanded access to its compassionate use programme in the US of its investigational candidate to include the treatment of children infected ...

AstraZeneca (AZ) and Merck’s – known as MSD outside the US and Canada – Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a ...

German company Merck KGaA has signed an exclusive licence agreement with Swiss biopharma company Debiopharm for its late-stage oncology asset xevinapant. Xevinapant is a potentially first-in-class ...

The US government has announced the ten drugs selected for the first round of pricing negotiations under President Biden’s Inflation Reduction Act (IRA). The IRA allows Medicare, the government health ...

Bryson DeChambeau is not your average golfer. He does things differently: he studies every move, challenges the rules and ultimately changes the game. Not everyone likes him, but they don’t have to – ...

Researchers from the Wellcome Sanger Institute, the University of Cambridge and collaborators have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a ...

The US health department has proposed three new models to help lower the cost of drugs, promote accessibility and improve quality of care for those enrolled in voluntary government health insurance ...

World Hepatitis Day takes place today, with this year’s theme, ‘I can’t wait’, highlighting the need to accelerate the fight against viral hepatitis to reach the 2030 elimination target.

Melanoma skin cancer cells harness a gene – usually used to create connections between nerves – to escape from their immediate area and invade new tissues, according to research from The Institute of ...

Eli Lilly and AbCellera are the latest contenders to join the fight against the novel coronavirus, after announcing they have partnered on the development of antibody therapies targeting the virus.

A group of scientists from the University of Surrey have shared findings from a seven-year research study, revealing that a new approach could be on the horizon for treating one of the most prevalent ...

Merck & Co – known as MSD outside the US and Canada – and Moderna have announced positive phase 2b trial results investigating the use of their personalised mRNA cancer vaccine, mRNA-4157/V940, in ...